DACRA-089 / Eli Lilly, Nordic Biosci - LARVOL DELTA

Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction-associated steatotic liver disease? (PubMed, Liver Int) - "Several pharmacological interventions (patchouli alcohol, KBP-089, 2,4-dinitrophenol methyl ether, adipoRon and atglistatin) and food supplementation (vitamin D or resveratrol) improve liver and muscle phenotypes in pre-clinical studies by increasing fatty acid oxidation and anti-inflammatory properties...This review supports that disturbances in inter-organ crosstalk are key pathophysiological mechanisms involved in MASLD and myosteatosis pathogenesis. Focusing on the skeletal muscle might offer new therapeutic strategies to treat MASLD by modulating the interactions between liver and muscles."

Journal • Review • Hepatology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. (PubMed, BMC Endocr Disord) - "DACRAs complement GLP-1 on food intake, body weight, and glucose tolerance indicating the potential for an add-on therapy."

Journal • Genetic Disorders • Obesity

A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM (clinicaltrials.gov) - P1; N=25; Terminated; Sponsor: KeyBioscience AG; N=36 ➔ 25; Recruiting ➔ Terminated; The trial was planned to be conducted in 4 cohorts but was terminated after completion of Cohort 2 for strategic reasons due to limited PD effects.

Clinical • Enrollment change • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus